Click here to close now.

Welcome!

News Feed Item

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013


Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Macular Edema . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Macular Edema . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Diabetic Macular Edema 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Diabetic Macular Edema 23
Subjects Recruited Over a Period of Time 27
Prominent Sponsors 28
Top Companies Participating in Diabetic Macular Edema Therapeutics Clinical Trials 30
Prominent Drug Comparison 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Regeneron Pharmaceuticals, Inc. 38
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Bayer AG 40
Clinical Trial Overview of Bayer AG 40
Alimera Sciences, Inc. 41
Clinical Trial Overview of Alimera Sciences, Inc. 41
Santen Pharmaceutical Co., Ltd. 42
Clinical Trial Overview of Santen Pharmaceutical Co., Ltd. 42
Bausch & Lomb Incorporated 43
Clinical Trial Overview of Bausch & Lomb Incorporated 43
Clinical Trial Overview of Top Institutes / Government 44
Diabetic Retinopathy Clinical Research Network 44
Clinical Trial Overview of Diabetic Retinopathy Clinical Research Network 44
National Eye Institute 45
Clinical Trial Overview of National Eye Institute 45
Johns Hopkins University 46
Clinical Trial Overview of Johns Hopkins University 46
Shahid Beheshti University of Medical Sciences 47
Clinical Trial Overview of Shahid Beheshti University of Medical Sciences 47
The University of Sydney 48
Clinical Trial Overview of The University of Sydney 48
Moorfields Eye Hospital NHS Foundation Trust 49
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 49
Medical University of Vienna 50
Clinical Trial Overview of Medical University of Vienna 50
Hong Kong Eye Hospital 51
Clinical Trial Overview of Hong Kong Eye Hospital 51
Federal University of Sao Paulo 52
Clinical Trial Overview of Federal University of Sao Paulo 52
University of Sao Paulo 53
Clinical Trial Overview of University of Sao Paulo 53
Five Key Clinical Profiles 54
Appendix 154
Abbreviations 154
Definitions 154
Research Methodology 155
Secondary Research 155
About GlobalData 155
Contact Us 155
Disclaimer 156
Source 156



List of Tables

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries, 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries, 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries, 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries, 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase, 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Market, Global, Suspended Clinical Trials, 2013* 23
Diabetic Macular Edema Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 24
Diabetic Macular Edema Therapeutics Market, Global, Terminated Clinical Trials, 2013* 25
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 29
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 31
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 33
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013* 35
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013* 37
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2013* 38
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 39
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2013* 40
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Alimera Sciences, Inc., 2013* 41
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Santen Pharmaceutical Co., Ltd., 2013* 42
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bausch & Lomb Incorporated, 2013* 43
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Diabetic Retinopathy Clinical Research Network, 2013* 44
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2013* 45
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2013* 46
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University of Medical Sciences, 2013* 47
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2013* 48
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Moorfields Eye Hospital NHS Foundation Trust, 2013* 49
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2013* 50
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Hong Kong Eye Hospital, 2013* 51
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2013* 52
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2013* 53



List of Figures

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries (%), 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries (%), 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries (%), 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 28
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 30
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
GlobalData Methodology 155


Read the full report:
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013
http://www.reportbuyer.com/pharma_healthcare/treatments/diabetic_macular...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
"We have a tagline - "Power in the API Economy." What that means is everything that is built in applications and connected applications is done through APIs," explained Roberto Medrano, Executive Vice President at Akana, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
"AgilData is the next generation of dbShards. It just adds a whole bunch more functionality to improve the developer experience," noted Dan Lynn, CEO of AgilData, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
The cloud has transformed how we think about software quality. Instead of preventing failures, we must focus on automatic recovery from failure. In other words, resilience trumps traditional quality measures. Continuous delivery models further squeeze traditional notions of quality. Remember the venerable project management Iron Triangle? Among time, scope, and cost, you can only fix two or quality will suffer. Only in today's DevOps world, continuous testing, integration, and deployment upend...
"We provide a web application framework for building really sophisticated web applications that run on a browser without any installation need so we get used for biotech, defense, and banking applications," noted Charles Kendrick, CTO and Chief Architect at Isomorphic Software, in this SYS-CON.tv interview at @DevOpsSummit (http://DevOpsSummit.SYS-CON.com), held June 9-11, 2015, at the Javits Center in New York
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect t...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...
"A lot of the enterprises that have been using our systems for many years are reaching out to the cloud - the public cloud, the private cloud and hybrid," stated Reuven Harrison, CTO and Co-Founder of Tufin, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society-changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his session at @ThingsExpo, Jason Mondanaro, Director, Product Management at Metanga, discussed how you can plan to cooperate, partner, and form lasting all-star teams to change the world...